Anhedonia and social adaptation predict substance abuse evolution in dual diagnosis schizophrenia

American Journal of Drug and Alcohol Abuse

Volumn 34, Issue 1, 2008, Pages 75-82

  Potvin, Stéphane ^a,b   Stip, Emmanuel ^a,b   Lipp, Olivier ^a,b   Roy, Marc André ^c   Demers, Marie France ^c   Bouchard, Roch Hugo ^c   Gendron, Alain ^d  

^a CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c CENTRE DE RECHERCHE DE L INSTITUT UNIVERSITAIRE EN SANTÉ MENTALE DE QUÉBEC   (Canada)

^d ASTRAZENECA   (United Kingdom)

Author keywords

Anhedonia; Schizophrenia; Social adaptation; Substance use disorders

Indexed keywords

CANNABIS; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT;

ADULT; ALCOHOLISM; ANHEDONIA; ARTICLE; CANNABIS ADDICTION; CLINICAL ARTICLE; DEPRESSION; FEMALE; HUMAN; LINEAR REGRESSION ANALYSIS; MALE; MENTAL DISEASE; PROGNOSIS; SCHIZOPHRENIA; SELF MEDICATION; SOCIAL ADAPTATION; SOCIAL BEHAVIOR; SUBSTANCE ABUSE;

ADULT; AFFECTIVE SYMPTOMS; ALCOHOL-RELATED DISORDERS; ANTIPSYCHOTIC AGENTS; ATTITUDE; BEHAVIOR, ADDICTIVE; COMORBIDITY; DIAGNOSIS, DUAL (PSYCHIATRY); FEMALE; HUMANS; MALE; MARIJUANA ABUSE; MODELS, PSYCHOLOGICAL; MOTIVATION; PROGNOSIS; PSYCHOTROPIC DRUGS; REGRESSION ANALYSIS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SELF MEDICATION; SOCIAL ADJUSTMENT; SUBSTANCE-RELATED DISORDERS;

EID: 37649004411     PISSN: 00952990     EISSN: 10979891     Source Type: Journal    
DOI: 10.1080/00952990701764631     Document Type: Article

References (25)

1. Kavannagh DJ, McGrath J, Saunders JB, Dore G, Clark D. Substance misuse in patients with schizophrenia. Drugs 2002; 62:743-755.
2. Regier DA, Farmer ME, Raes DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK. Comorbidity of mental disorders with alcohol and other drug abuse: Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990; 264:2511-2518.
3. Khantzian EJ. The self-medication hypothesis of substance use disorders: A reconsideration and recent applications. Har Rev Psychiatry 1997; 4:231-244.
4. Khantzian EJ. The self-medication hypothesis of substance use disorders: Focus on heroin and cocaine dependence. Am J Psychiatry 1985; 142:1259-1264.
5. Mueser KT, Yarnold PR, Rosenberg SD, Swett C, Miles KM, Hill D. Substance use disorder in hospitalized severely mentally ill psychiatric patients: Prevalence, correlates, and subgroups. Schizophr Bull 2000; 26:179-192.
6. Potvin S, Sepehry AA, Stip E. A meta-analysis of negative symptoms in dual diagnosis schizophrenia. Psychol Med 2006; 36:431-440.
7. Talamo A, Centorrino F, Tondo L, Dimitri A, Hennen J, Baldessarini RJ. Comorbid substance-use in schizophrenia: Relation to positive and negative symptoms. Schizophr Res 2006; 86(1-3):251-255.
8. Tien AY, Anthony JC. Epidemiological analysis of alcohol and drug use as risk factors for psychotic experiences. J Nerv Ment Dis 1990; 178:473-480.
9. Mueser KT, Drake RE, Wallach MA. Dual diagnosis: A review of etiological theories. Addict Behav 1998; 23:717-734.
10. Veen ND, Selten JP, van der Tweel I, Feller WG, Hoek HW, Kahn RS. Cannabis use and age at onset of schizophrenia. Am J Psychiatry 2004; 161:501-506.
11. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: Longitudinal prospective study. Brit Med J 2002; 325:1212-1213.
12. Henquet C, Murray R, Linszen D, van Os J. The environment and schizophrenia: The role of cannabis use. Schizophr Bull 2005; 31:608-612.
13. Bersani G, Orlandi V, Kotzalidis GD, Pancheri P. Cannabis and schizophrenia: Impact on onset, course, psychopathology and outcomes. Eur Arch Psychiatr Clin Neurosci 2002; 252:86-92.
14. Serper MR, Chou JCY, Allen MH, Czobor P, Cancro R. Symptomatic overlap of cocaine intoxication and acute schizophrenia at emergency presentation. Schizophr Bull 1999; 25:387-394.
15. Potvin S, Stip E, Lipp O, Élie R, Mancini-Marië A, Demers MF, Roy MA, Bouchard RH, Gendron A. Quetiapine in patients with schizophreniaspectrum and substance use disorders: An open-label trial. Curr Med Res Op 2006; 22:1277-1285.
16. Srisurapanont M, Maneeton B, Maneeton N. Quetiapine for schizophrenia. Cochrane Database Syst Rev 2004; 2:CD000967.
17. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261-276.
18. Sobell LC, Sobell MB. Timeline follow-back: A technique for assessing self-reported alcohol consumption. In Measuring Alcohol Consumptions: Psychosocial and Biochemical Methods. Littren RZ, Allen JP, eds. Towota: Humana Press, 1992; 41-72.
19. Drake RE, Osher FC, Noordsy DL, Hurlburt SC, Teague GB, Beaudett MS. Diagnosis of alcohol use disorders in schizophrenia. Schizophr Bull 1990; 16(1):57-67.
20. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr Res 1990; 3:247-251.
21. Chapman LJ, Chapman JP, Raulin ML. Scales for physical and social anhedonia. J Abnorm Psychol 1976; 4:374-382.
22. Weissman MM, Sholomskas D, John K. The assessment of social adjustment: An update. Arch Gen Psychiatry 1981; 38:1250-1258.
23. Hunt GE, Bergen J, Bashir M. Medication compliance and comorbid substance abuse in schizophrenia: An impact on community survival 4 years after relapse. Schizophr Res 2002; 54:253-264.
24. Margolese HC, Negrete JC, Tempier R, Gill K. A 12-month prospective follow-up study of patients with schizophrenia-spectrum disorders and substance abuse: Changes in psychiatric symptoms and substance use. Schizophr Res 2006; 83(1):65-75.
25. Negrete JC. Clinical aspects of substance abuse in persons with schizophrenia. Canad J Psychiatry 2003; 55:109-113.